Today: 30 April 2026
Browse Category

NASDAQ:ALVO 18 December 2025

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 18.12.2025

Vital Farms (VITL) closed at $32.25, well below a fair value estimate of $49.45, after a volatile year and 5% recent pullback. Alvotech (ALVO) dropped 36% in three months to $5, far under analyst targets, amid FDA inspection concerns. EOG Resources secured a $3 billion credit line and named John D. Chandler to its board as it faces operational and ESG risks during Encino integration.
18 December 2025
··

Stock Market Today

  • Big Tech Earnings, Fed Chair Powell's Plans, Iran Tensions Impact Oil Prices
    April 30, 2026, 9:13 AM EDT. Big Tech earnings from four of the Magnificent Seven firms beat expectations, but stocks showed mixed reactions amid growing AI investment plans. The Federal Reserve paused interest rate hikes in a rare 1992-level divided vote, with Chair Jerome Powell signaling he will remain as a governor post-chairmanship amid a Justice Department probe. Powell's potential successor, Kevin Warsh, cleared a Senate committee, suggesting policy shifts could follow. Meanwhile, oil prices surged to $126 a barrel due to escalating tensions around the Strait of Hormuz, with President Trump maintaining a U.S. blockade linked to nuclear negotiations with Iran. These developments are shaping investor sentiment and market direction on Thursday.

Latest article

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

QUALCOMM Incorporated (QCOM) Stock Jumps as AI Data-Center Bet Offsets Weak Forecast

30 April 2026
Qualcomm shares rose 10.3% premarket Thursday after CEO Cristiano Amon said the smartphone market had bottomed and highlighted progress in data-center chips. Fiscal Q2 revenue fell 3% to $10.6 billion, with handset revenue down 13% but automotive up 38%. The Q3 forecast missed Wall Street estimates. Qualcomm expects chip sales to Chinese handset makers to recover after Q3.
Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

30 April 2026
Eli Lilly raised its 2026 revenue forecast by $2 billion after first-quarter sales jumped 56% to $19.8 billion, driven by Mounjaro and Zepbound, which brought in $12.8 billion. Adjusted earnings reached $8.55 per share. The company cited strong demand but noted lower realized prices and competition from Novo Nordisk remain risks. Foundayo, Lilly’s new oral GLP-1 pill, launched in April but was not included in the quarter’s results.
Go toTop